-
March 18, 2010
Based on our Pharmacor advisory service entitled Alzheimer’s Disease, Decision Resources is offering an exclusive analyst call entitled Assessing the Impact of Dimebon’s Clinical Trial Failure on the Alzheimer’s Disease Drug Market. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call will be held on March 18, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
Click here to view the invite.
Read More
-
March 16, 2010
Based on our Pharmacor advisory service entitled Human Immunodeficiency Virus, Decision Resources is offering an exclusive analyst call entitled The Increasing Challenges of the Maturing HIV Drug Market: Will Gilead’s Quad or Merck’s Vicriviroc Be Able to Compete? Because this presentation will feature report updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call will be held on March 16, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
Click here to view the invite.
Read More
-
March 5, 2010
Based on our Pharmacor advisory service entitled Type 2 Diabetes, Decision Resources is offering an exclusive Pharmacor analyst call entitled Avandia Makes Headlines Again: How Will the Renewed Controversy Impact the Type 2 Diabetes Drug Market? Because this analyst call features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on March 5, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
Click here to view the invite.
Read More
-
February 25, 2010
Based on our Pharmacor advisory service entitled Fibromyalgia, Decision Resources is offering an exclusive Pharmacor analyst call entitled Despite Safety Concerns, Sodium Oxybate is Poised for Approval in the U.S. for Fibromyalgia: Will It See Any Uptake in Primary Care? Because this analyst call features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on February 25, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
Click here to view the invite.
Read More
-
February 12, 2010
Based on our Pharmacor advisory service entitled Gastric Cancer, Decision Resources is offering an exclusive Pharmacor analyst call entitled Herceptin is Poised to Launch in Europe for Gastric Cancer: Will It Blaze the Trail for Other Targeted Agents in This Indication? Because this analyst call features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on February 12, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
February 11, 2010
Based on our Pharmacor advisory service entitled Obesity Decision Resources is offering an exclusive Pharmacor analyst call entitled How Will Sibutramine’s Suspension in Europe Affect its Future in the United States and What Now Lies Ahead for the Obesity Drug Market? Because this analyst call features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on February 11, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
February 10, 2010
Based on our Pharmacor advisory service entitled Rheumatoid Arthritis, Decision Resources is offering an exclusive Pharmacor analyst call entitled Rheumatoid Arthritis: Will Actemra Ultimately Steal Market Share from the TNF-Alpha Inhibitors? Because this analyst call features major updates, it is ONLY available to purchasers this Pharmacor advisory service.
This analyst call was held on February 10, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
February 4, 2010
Based on our Pharmacor advisory service entitled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms Decision Resources is offering an exclusive Pharmacor analyst call entitled Benign Prostatic Hyperplasia: How Will the Discontinuation of Ozarelix and Launches of PRX-302 and NX-1207 Impact the Novel Injectables Landscape for BPH? Because this analyst call features major updates, it is ONLY available to purchasers of this Pharmacor advisory service.
This analyst call was held on February 4, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
January 15, 2010
Based on our Pharmacor advisory service entitled Prostate Cancer, Decision Resources is offering an exclusive Pharmacor analyst call entitled Sanofi-Aventis’s Novel Agent Emerges as an Effective Treatment for Prostate Cancer: Which Current Drugs Will Lose Market Share to Cabazitaxel? Because this analyst call will feature major updates, it is ONLY available to purchasers of one or both of this Pharmacor advisory service.
This analyst call was held on January 15, 2010. Contact us to learn how you can purchase this Pharmacor advisory service and access a recorded playback of this event.
Click here to view the invite.
Read More
-
January 14, 2010
Based on our Pharmacor advisory services entitled Methicillin-Resistant Staphylococcus aureus and Community-Acquired Pneumonia, Decision Resources is offering an exclusive Pharmacor analyst call entitled Ceftobiprole’s Non-Approval in the U.S. Changes the Forecast for MRSA and Community-Acquired Pneumonia – Who Will Get the Projected $150 Million? Because this analyst call features major updates, it is ONLY available to purchasers of one or both of these Pharmacor advisory services.
This analyst call was held on January 14, 2010. Contact us to learn how you can purchase one or both of these Pharmacor advisory services and access a recorded playback of this event.
Click here to view the invite.
Read More
-
December 9, 2009
Based on our 2009 Pharmacor Breast Cancer report, Decision Resources is offering an exclusive Pharmacor analyst call entitled Vying for Market Share in Triple Negative Breast Cancer - Will BSI-201 be a Worthy Competitor to Avastin? Because this analyst call features report findings, it is ONLY available to purchasers of this report.
This analyst call was held on December 9, 2009. Contact us to learn how you can purchase this report and access a recorded playback of this event.
Click here to view the invite.
Read More
-
November 20, 2009
Based on our 2009 Pharmacor Systemic Lupus Erythematosus report, Decision Resources is offering an exclusive analyst call entitled After 50 Years, a New Lupus Drug Finally Emerges – If Approved, How Will Benlysta Impact the Market? Because this analyst call features major report findings, it is ONLY available to purchasers of this report.
This analyst call was held on November 20, 2009. Contact us to learn how you can purchase this report and access a recorded playback of this event.
Click here to view the invite.
Read More
-
November 19, 2009
Based on our 2009 Pharmacor Hepatitis C Virus report, Decision Resources is offering an exclusive analyst call entitled The Battle for Market Supremacy in Hepatitis C Virus: Which Drug Will Emerge on Top – Telaprevir or Boceprevir? Because this analyst call features major report findings, it is ONLY available to purchasers of this report.
This analyst call was held on November 19, 2009. Contact us to learn how you can purchase this report and access a recorded playback of this event.
Click here to view the invite.
Read More
-
November 17, 2009
Based on our 2009 Pharmacor Obesity report, Decision Resources is offering an exclusive analyst call entitled Three Late-Stage Obesity Therapies Close in on the Finish Line – Which Agents Will Have the Greatest Impact on the Market? Because this analyst call features major report findings, it is ONLY available to purchasers of this report.
This analyst call was held on November 17, 2009. Contact us to learn how you can purchase this report and access a recorded playback of this event.
Click here to view the invite.
Read More
-
November 10, 2009
Based on our 2009 Pharmacor Rheumatoid Arthritis report, Decision Resources is offering an exclusive analyst call entitled Do Newcomers Cimzia and Simponi Pose a Threat to Established TNF-alpha Inhibitors in the Rheumatoid Arthritis Market? Because this analyst call will feature major report findings, it is ONLY available to purchasers of this report.
This analyst call was held on November 10, 2009. Contact us to learn how you can purchase this report and access a recorded playback of this event.
Click here to view the invite.
Read More